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Abstract
Diabetes leads to complications in selected organ systems, and vascular endothelial cell (EC) dysfunction and loss is the key
initiating and perpetuating step in the development of these complications. Experimental and clinical studies have shown
that hyperglycemia leads to EC dysfunction in diabetes. Vascular stem cells that give rise to endothelial progenitor cells
(EPCs) and mesenchymal progenitor cells (MPCs) represent an attractive target for cell therapy for diabetic patients.
Whether these vascular stem/progenitor cells succumb to the adverse effects of high glucose remains unknown. We sought
to determine whether adult vascular stem/progenitor cells display cellular activation and dysfunction upon exposure to
high levels of glucose as seen in diabetic complications. Mononuclear cell fraction was prepared from adult blood and bone
marrow. EPCs and MPCs were derived, characterized, and exposed to either normal glucose (5 mmol/L) or high glucose
levels (25 mmol/L). We then assayed for cell activity and molecular changes following both acute and chronic exposure to
high glucose. Our results show that high levels of glucose do not alter the derivation of either EPCs or MPCs. The adult
blood-derived EPCs were also resistant to the effects of glucose in terms of growth. Acute exposure to high glucose levels
increased caspase-3 activity in EPCs (1.4x increase) and mature ECs (2.3x increase). Interestingly, MPCs showed a transient
reduction in growth upon glucose challenge. Our results also show that glucose skews the differentiation of MPCs towards
the adipocyte lineage while suppressing other mesenchymal lineages. In summary, our studies show that EPCs are resistant
to the effects of high levels of glucose, even following chronic exposure. The findings further show that hyperglycemia may
have detrimental effects on the MPCs, causing reduced growth and altering the differentiation potential.
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Introduction
Vascular dysfunction is the underlying cause of each of the
clinical manifestations of long-term diabetes [1,2]. It presents as
both micro- (cardiomyopathy, retinopathy, nephropathy, neurop-
athy) and macro-(atherosclerosis) angiopathies [3]. It is now widely
accepted that in each target organ, problems arise from sustained
hyperglycemia acting directly on the endothelial cells (ECs) [4,5].
With chronic insult, biochemical alterations occur in the ECs that
result in structural and functional variations in blood vessels [1].
Over time, and with the aberration of entire vascular networks,
blood flow is altered and tissues become ischemic [6]. This induces
a variety of complications that differ depending on the target
organ vascular bed. We hypothesized that a balance exists
between uncontrolled neovascularization and fibrosis [2], and will
shift to one side depending on the tissue microenvironment (i.e.
growth factors, matrix proteins) and the intrinsic properties of the
ECs, as well as the presence of other risk factors (i.e. hyperlipi-
demia, hyperinsulinemia).
An intact vascular system is essential for the continued delivery
of oxygen and nutrients to the tissue and the removal of waste
products- both of which are required to maintain proper tissue
functioning. ECs and perivascular cells work together, and are
necessary, for the formation of stable and functional vascular
networks. With the discovery of postnatal endothelial progenitor
cells (EPCs) [7,8], a new concept of neovascularization has
emerged. It is now understood that complete vasculogenesis (i.e.
the differentiation of progenitor cells into vascular cells) is able to
take place postnatally [9,10]. With local damage or ischemia,
progenitor cells are stimulated to mobilize from the bone marrow
and can congregate in areas of injury through the use of cytokines
and other homing mechanisms [11]. Once situated, they can
incorporate and differentiate into vascular cells in order to restore
homeostasis. From this viewpoint, an insufficient number of
progenitor cells may cause or contribute to any ischemic disease.
The insufficiency in progenitor cells may be caused by a number of
factors such as impaired bone marrow release, loss of migratory
ability, loss of differentiation potential, or shortened survival time
in the peripheral circulation.
The idea of a specific vascular stem cell (VSC) population is one
that is steadily gaining recognition. VSCs are a sub-population of
CD133+ cells that are able to differentiate into mature cells of the
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marrow, but can also be derived from the mononuclear cell layer
of peripheral blood, making them an easily attainable source of
cells. The existence of a common vascular stem/progenitor cell
that can be derived from adult human blood samples highlights
the feasibility of therapeutic vasculogenesis for long-term diabetic
patients. Although we know VSCs may provide the basis for
vasculogenesis in a nude mouse model [14], whether they are able
to restore vascular homeostasis in an in vivo diabetic setting remains
to be determined. The effects of high glucose on the functionality
of both EPCs and MPCs must be elucidated firstly. To date, the
role of MPCs in diabetic complications has not been investigated,
and much of the work done on EPCs (short-term colonies; 2–
4 days in culture) is confounded by the presence of hematopoietic/
monocytic cells within the studies [15,16]. These ‘early’ cells are
characterized by Ulex europaeus agglutinin binding and DiI-
labeled acetylated-low density lipoprotein (LDL) uptake
[15,17,18]. Both of these assays are not specific to ECs [19,20].
Therefore, a combination of both phenotypic and functional
properties must be used to unambiguously identify both EPCs and
MPCs so as not to impair the results of the studies. We herein
determine the precise role of vascular EPCs and MPCs in a high
glucose setting in order to highlight their potential application in
diabetes therapy.
Methods
Isolation, culture, and differentiation of VSCs
All experiments were approved by the Research Ethics Board at
the University of Western Ontario, London Ontario. Normal
adult peripheral blood (US Biological; age 26.1666.79 yrs) and
fresh bone marrow samples (Lonza Inc.) were obtained and
mononuclear cell fraction was prepared as shown by us previously
[21]. To obtain adult blood EPCs (abEPCs), cell suspensions were
cultured on FN-coated (FN; 1 mg/cm
2; Millipore) plates in
modified endothelial cell media: complete Endothelial Basal
Media-2 (EMB2; Lonza Inc.) supplemented with 35% fetal bovine
serum (FBS; Lonza Inc.) and EBM2 SingleQuots (Lonza Inc.).
The media was changed every day until colonies began to appear.
Thereafter the media was changed every other day. All subcultures
were then performed with EBM2/20% FBS/SingleQuots media.
Bone marrow samples were cultured on FN-coated plates in
DMEM (Invitrogen) media, supplemented with 20% FBS, 1X PSF
(antibiotic-antimycotic solution; CellGro Mediatech Inc.), and no
additional growth factors. To assess the effect of high levels of
glucose on abEPC and bone marrow MPC (bmMPC) differenti-
ation, the media was supplemented with 25 mmol/L glucose from
the initial plating. All other experiments were conducted on
passage 2–6 cells with 3 technical and 3–5 biological replicates.
Normal human dermal microvascular endothelial cells
(HDMECs; CC-2516, Lonza Inc.) and human cord blood-derived
EPCs (cbEPCs; derived from cord blood using the same protocol
as mentioned above for adult blood; 2C-150A; Lonza Inc.) were
used as control for the abEPCs. Human umbilical artery smooth
muscle cells (uaSMC) were used as control for the bmMPCs.
Cell staining
Cultured cells were trypsinized and plated (10,000 cells/cm
2)
on FN-coated 8-chambered slides one day prior to staining to
allow for attachment of cells. Immunofluorescence staining for
endothelial cell markers was carried out using goat anti-human
CD31 (1:200; Santa Cruz Biotechnology Inc.), rabbit anti-human
Von Willebrand Factor (vWF, 1:200; DakoCytomation), and
goat anti-human vascular endothelial (VE)-Cadherin (1:200;
Santa Cruz Biotechnology Inc). For the mesenchymal cells, we
used mouse anti-human a-smooth muscle actin (1:200; Sigma),
mouse anti-human CD90 (1:200; Abcam), mouse anti-human
NG2 (1:200; Abcam), and mouse anti-human platelet-derived
growth factor receptor-b (PDGF-Rb, 1:200; R&D Systems)
antibodies followed by FITC- or Alexa488-conjugated secondary
antibodies. Slides were subjected to a nuclei counterstain using
DAPI and mounted using Fluoromount mounting medium.
Images were taken using Olympus BX-51 fluorescent microscope
and Spot Basic software.
RNA isolation and qRT-PCR
Using RNeasy Mini Plus or Micro Plus (Qiagen, Mississauga,
Ontario), total RNA was extracted from the cells grown in culture.
Purity of the RNA samples was determined by measuring the
absorbance at 260:280 nm in GeneQuant Spectrophotometer
(Pharmacia Biotech). The quantity was determined by QubitH
Broad Range RNA assay in the QubitH Fluorometer (Invitrogen).
cDNA synthesis was performed with 200 ng of RNA using iScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA).
Primers used for RT-PCR are listed in Table 1. RT-PCR
reactions consisted of 10 mL 2X SYBR Advantage qPCR premix
(Clontech Laboratories, Inc., Mountain View, CA), 2 mL of both
forward and reverse primers (at a 10 mM concentration), 2 mL
cDNA, and 6 mLo fH 2O. All reactions were performed for 40
cycles using the following temperature profiles: 95uC for 5 minutes
(initial denaturation); 55uC for 10 seconds (annealing); and 72uC
for 12 seconds (extension). 18S rRNA was used as the housekeep-
ing gene. PCR specificity was determined by both the melting
curve analysis and gel electrophoresis and the data was analyzed
by standard curve method.
Cell growth assay
The growth of the abEPCs and bmMPCs was assayed by
plating the cells in triplicates on FN-coated multiwell plates
(Corning Life Sciences) at a density of 2500 cells/cm
2. The EPCs
were cultured in complete EBM2/20% FBS media with or
without the addition of high glucose (25 mmol/L; 450 mg/dL).
Cell number was determined on days 1, 6, and 12 using Scepter
2.0 Automated Cell Counter (Millipore). The histogram gating
was adjusted to specifically measure live cells. bmMPCs were also
plated at a density of 2500 cells/cm
2 in multiwall plates. However,
the cells were cultured in DMEM/10% FBS media with or
without the addition of 25 mmol/L glucose for 1, 4, and 12 days.
The data was presented as cell counts. The results were also
confirmed by colorimetric assay utilizing tetrazolium salt reagent
(WST-1, Clontech, Mountain View, CA). Following incubation,
the absorbance was measured at 450 nm using Multiskan FC
Microplate Photometer (Thermo Scientific, USA) with 690 nm
absorbance as the reference point.
Caspase-3 activity
We also tested the effect of high glucose levels on caspase-3
activity (BF3100; R&D Systems) in serum-reduced media (EBM2/
1% FBS for endothelial cell types and DMEM/1% FBS for
mesenchymal cell types). The cells were cultured for up to 4 days
(longer time periods were not possible as serum reduction itself
causes cell death) with or without the addition of 25 mmol/L
glucose and cell lysates were prepared. To measure caspase-3
activity, a caspase-specific peptide conjugated to p-nitroaniline was
added to the lysates and the cleavage product was quantified by
measuring absorbance at 405 nm.
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A migration assay was performed on both abEPCs and
bmMPCs using FN-coated 6.5-mm Transwell inserts with 8.0-
mm pores (BD Falcon Cell Culture inserts; BD Biosciences).
abEPCs were trypsinized and re-suspended in control (EBM2/1%
FBS) or high glucose (EBM2/1% FBS +25 mmol/L glucose)
media. One hundred mL of cell suspension was added to the inserts
in triplicates, and at a density of 10,000 cells/insert. The lower
chambers contained 10 ng/mL basic fibroblast growth factor
(bFGF; 233-FB-025, R&D Systems). The cell density used in this
assay was optimized for endothelial cells in our pilot studies to
provide a robust measure of cell migration. Twenty four hours
later, cells on the upper insert were removed and cells in the lower
chamber that had migrated through the pore were trypsinized.
The cell suspension was centrifuged, re-suspended in media, and
added to 96-well plates in order to be measured by the Multiskan
Table 1. Primer sequence information for qRT-PCR.
Gene Length (bp) Source (catalogue number)
Adipogenesis markers
CCAAT/enhancer binding protein alpha (C/EBPa) 88 bp Qiagen (QT00203357)
Peroxisome proliferator-activated receptor c2 (PPARc2) 134 bp 59R39 ATTGACCCAGAAAGCGATTCC
CAAAGGAGTGGGAGTGGTCT
Chondrogenesis markers
NK3 homeobox 2 (Nkx3.2) 100 bp Qiagen (QT01079582)
Runt-related transcription factor 2 (Runx2) 102 bp Qiagen (QT00020517)
Sex determining region Y-box 9 (Sox9) 111 bp Qiagen (QT00001498)
Endothelial cell markers
CD31 144 bp Qiagen (QT00081172)
CD34 106 bp Qiagen (QT00056497)
Vascular endothelial growth factor receptor 2 (VEGFR-2) 78 bp Qiagen (QT00069818)
Vascular endothelial cadherin (VE-cadherin) 109 bp Qiagen (QT00013244)
Von Willebrand factor (vWF) 108 bp Qiagen (QT00051975)
Endothelial cell activation markers
Endothelin 1 (ET-1) 166 bp Qiagen (QT00088235)
Endothelial selectin (E-selectin) 96 bp Qiagen (QT00015358)
Intercellular adhesion molecule 1 (ICAM1) 84 bp Qiagen (QT00074900)
Extracellular matrix (ECM) proteins
Fibronectin 119 bp Qiagen (QT00038024)
Collagen 1 118 bp Qiagen (QT00037793)
Collagen 3 95 bp Qiagen (QT00058233)
Collagen 4 119 bp Qiagen (QT00005250)
Mesenchymal cell markers
Alpha smooth muscle actin (a-SMA) 83 bp Qiagen (QT00088102)
Calponin 78 bp Qiagen (QT00067718)
Myosin heavy chain (MHC) 130 bp Qiagen (QT00069391)
NG2 128 bp Qiagen (QT00079884)
Platelet-derived growth factor receptor b (PDGFR-b) 102 bp Qiagen (QT00082327)
Osteogenesis markers
Osterix (SP7) 120 bp Qiagen (QT00213514)
Runt-related transcription factor 2 (Runx2) 102 bp Qiagen (QT00020517)
Oxidative stress markers
Catalase (Cat) 60 bp Qiagen (QT00079674)
Glutathione peroxidase 1 (GPx) 105 bp Qiagen (QT00203392)
Heme oxygenase 1 (HO-1) 99 bp Qiagen (QT00092645)
NADPH oxidase (p22 Phox) 106 bp Qiagen (QT00082481)
Inducible NOS (NOS2) 92 bp Qiagen (QT00068740)
Superoxide dismutase 1 (SOD-1) 150 bp Qiagen (QT01671551)
Housekeeping gene
18S rRNA 149 bp Qiagen (QT00199367)
doi:10.1371/journal.pone.0038752.t001
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similarly but with pre-optimized 25,000 cells/cm
2. The lower
chambers in bmMPC migration experiments contained 10%
serum as the chemoattractant.
MPC differentiation assay
A differentiation assay was conducted on bmMPCs to assess
whether they retain their multipotential nature under high glucose
conditions. Cells were treated with control or high glucose media
(DMEM/10%) for 7 days before the differentiation experiments.
To induce differentiation, bmMPCs were seeded at a density of
40,000 cells/cm2 on 12-well plates in specific differentiation
media (StemProH Adipogenesis/Chondrogenesis/Osteogenesis
Differentiation media; Invitrogen). Media was changed every
other day. RNA was isolated from cells after 7 and 14 days to
perform qRT-PCR in order to quantify the differentiation
potential. We measured peroxisome proliferator activated recep-
tor-c2 and C/EBP a for adipogenesis, Runx2 and osterix (SP7) for
osteogenesis, and Sox9, Nkx3.2, and Runx2 for chondrogenesis.
These transcription factors are essential for the differentiation of
multipotential cells into the lineages indicated [22,23].
Statistical analysis
The data were expressed as means 6 SEM. Where appropriate,
analysis of variance (ANOVA) followed by two-tailed student’s
unpaired t-tests were performed. P values ,0.05 were considered
statistically significant.
Results
Isolation and characterization of abEPCs and bmMPCs
Culture of the adult blood cells in EBM-2 media supplemented
with SingleQuots induced differentiation of the cells into the
endothelial lineage (abEPCs). Culture of blood-derived cells in
high glucose media did not significantly alter the number of
colonies (Figure 1A). No colonies appeared in either control or
high glucose level conditions prior to day 14 (data not shown;
plates were screened daily using phase contrast microscopy).
abEPCs were then characterized through RT-PCR to confirm
expression of endothelial cell-selective genes and through immu-
nocytochemistry to properly localize the cellular markers. cbEPCs
and HDMECs were used as controls. RT-PCR confirmed the
expression of 5 genes of known significance to endothelial cells:
CD31, CD34, VEGFR-2, VE-cadherin, and vWF (Figure 1B).
The expression of all endothelial-specific genes tested, except for
VEGFR-2, was significantly higher in abEPCs as compared to
mature HDMECs (Figure 1B). Immunostaining showed both
CD31 and VE-cadherin localized to the cell membrane of
abEPCs, as anticipated (Figure 1C). vWF, an intracellular protein
stored in Weible Palade bodies, showed intracellular localization.
bmMPC colonies appeared within the first week of culture.
Similar to the abEPC preparations, high levels of glucose did not
significantly affect the number of colonies derived (Figure 1A).
MPCs were then subcultured and compared to umbilical artery
smooth muscle cells (uaSMCs) for expression of mesenchymal
markers. bmMPCs expressed mRNA for all mesenchymal markers
tested (Figure 1D). Interestingly, PDGFR-b was highly expressed
in bmMPCs as compared to mature uaSMCs (Figure 1D;
p,0.05). Other markers of mesenchymal lineage showed signif-
icantly lower expression in the bmMPCs. Positive staining was
observed for CD90, NG2, PDGFR-b, and a-SMA in bmMPCs
(Figure 1E). CD90, NG2, PDGFR-b were localized to the cell
membrane, whereas a-SMA was intracellular, consistent with
actin fiber staining.
High glucose levels do not alter abEPC growth and
migration
We wanted to know whether acute and chronic exposure to
high levels of glucose would alter abEPC growth. We cultured
abEPCs for a period of 12 days in EBM-2/20% FBS supple-
mented with either 5 mmol/L glucose (control) or 25 mmol/L
glucose (high glucose, HG). We chose to culture the cells in normal
serum levels because this setting would be reminiscent of the in vivo
conditions, and allow us to study the effect of chronically elevated
glucose levels without the confounding toxicity associated with
serum-free media. Our results show that the growth of abEPCs,
and even HDMECs, is not affected by high levels of glucose
(Figure 2A). An increase in total cell number was noted at day 6 in
the abEPCs. However, this increase was normalized (relative to
control media containing normal glucose levels) by day 12. We
then plated a high density of cells and assessed the cell capacity for
survival in depleted media (1% FBS), and how the addition of high
glucose might impede this process. Addition of high glucose in 1%
serum media reduced the cell number at 24 hours but had no
effect at day 4 (data not shown). To confirm that the reduction in
cell number was due to apoptosis, we measured caspase-3 activity
in the abEPCs and HDMECs. Our results show a slight but
significant increase in caspase-3 activity in abEPCs (1.4x increase
as compared to control media without high glucose) (Figure 2B).
Interestingly, the same conditions led to a 2.3x increase in caspase-
3 activity in the mature HDMECs (Figure 2B). As the cells were
plated under identical conditions (media, cell density, plate
coating), these data suggest that abEPCs are resistant to glucose-
induced toxicity as compared to the mature HDMECs.
Next, we tested whether high glucose causes changes in bFGF-
induced migration of abEPCs. We treated abEPCs and HDMECs
to normal glucose or high glucose levels in EBM-2/1%FBS. The
cells were seeded on transwell inserts and the lower chamber
contained 10 ng/mL bFGF. Our results show no significant
alteration of these cellular processes in both EC types in the
presence or absence of high levels of glucose (Figure 2C).
HG significantly alters the growth and migration of
bmMPCs
MPCs were also subjected to specific cellular activity assays in
order to test their functional characteristics in a high glucose
setting. Similar to the abEPC experiments, long-term growth of
MPCs was measured over the course of 12 days. Hyperglycemic
bmMPCs showed a significant decrease in cell number on day 1
(Figure 2D). However, with long-term culture in high glucose
media the growth was seemingly unaffected, as cell number had
normalized to control cells by day 4. Similarly, no significant
changes were observed in serum-depleted media (data not shown).
We then measured bmMPC migration using a potent mesenchy-
mal chemoattractant, FBS. Our results show that cell migration of
bmMPCs was reduced by nearly 50% in the hyperglycemic group
after 24 hours (Figure 2E).
Effect of glucose on cellular activation, matrix protein
expression, and redox-sensitive enzymes
We have previously shown altered cellular activity of ECs in
high glucose conditions and in target organs of diabetic
complications [24–26]. These altered activities include changes
in the redox enzymes, expansion of extracellular matrix, and
vasoactive factor alteration. We wanted to determine whether
long-term culture of vascular progenitor cells would lead to similar
alterations. Therefore, we cultured the cells in complete media
(EBM-2/20% FBS with or without 25 mmol/L glucose) and
VSC Responses to High Glucose
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activation genes (endothelin-1, ET-1; E-selectin; and intercellular
adhesion molecule-1, ICAM-1), matrix protein genes (collagens
1,3,4; and fibronectin), and oxidative stress genes (catalase, Cat;
glutathione peroxidase, GPx; heme oxygenase-1, HO-1; NADPH
oxidase, p22 Phox; inducible nitric oxide synthase, NOS2; and
superoxide dismutase-1, SOD-1). Interestingly, no significant
effect of high levels of glucose was noted in endothelial cell
activation, oxidative stress parameters, and matrix proteins at
day 1, day 3, or day 14 (Figure 3). Analysis of bmMPCs also
showed no changes in oxidative stress markers (Figure 4A).
Significantly increased levels of matrix proteins (collagen 3,
collagen 4, and fibronectin) in high glucose-treated uaSMCs were
seen (Figure 4B). These same matrix protein mRNA levels were
significantly reduced in the bmMPCs.
Altered differentiation potential of MPCs
We performed mesenchymal differentiation assays on the
bmMPCs to assess their ability to differentiate into adipocytes,
chondocytes, and osteocytes with the addition of high glucose. The
cells were pre-treated with high levels of glucose for 7 days prior to
culture in the differentiation media. qRT-PCR was used to
examine the expression of specific transcription factors involved in
the differentiation process (adipogenesis was assessed by C/EBPa
and PPARc2 (Figure 5A); chondrogenesis by Sox9, Nkx3.2, and
Runx2 (Figure 6A); and osteogenesis by Runx2 and osterix/SP7
(Figure 7A). High glucose drastically increased the differentiation
of bmMPCs into adipocytes, as assessed by C/EBPa and PPARc2
induction at day 7 (Figure 5B and 5C). At day 14, PPARc2 levels
in cells exposed to high glucose were similar to cells in the normal
glucose media (Figure 5D); however, C/EBPa levels remained
significantly higher (Figure 5E). Next, we assayed for osteogenic
differentiation by measuring levels of osteogenic transcription
factors Runx2 and osterix/SP7 (Figure 6A). Analysis of cells
exposed to the differentiation media at day 14 showed that high
glucose prevented Runx2 induction (Figure 6B) and significantly
reduced osterix/SP7 induction (Figure 6C). Lastly, we determined
whether glucose regulates chondrogenesis in bmMPCs. Sox9
mRNA levels were found to be elevated in control cells exposed to
the chondrogenic media at day 7, which was not observed in cells
Figure 1. Characterization of human adult blood-derived EPCs (abEPCs) and bone marrow-derived MPCs (bmMPCs). (A) abEPCs
(n=9) and bmMPCs (n=6) were derived from the mononuclear cell layer of adult peripheral blood samples and bone marrow samples, respectively.
No significant change in the number of abEPC and bmMPC colonies was seen with the addition of high glucose (25 mmol/L) to the culture medium.
(B) abEPCs were characterized through quantitative RT-PCR analysis for expression of known EC-markers: CD31, CD34, VE-cadherin, vWF, and VEGFR-2
[mRNA data normalized to 18S rRNA and presented relative to HDMECs; *p,0.05 compared to HDMECs; n=3]. (C) abEPCs were further characterized
through immunostaining for antibodies against cell surface markers CD31 and VE-cadherin, and intracellular marker vWF [Blue: DAPI for nuclear
staining; Green: Alexa Fluorochrome 488; scale bar represents 100 mm]. (D) Similarly, qRT-PCR analysis of bmMPCs showed expression of
mesenchymal markers: calponin, a-SMA, MHC, NG2, and PDGFR-b [data normalized to 18S rRNA and presented relative to uaSMCs; *p,0.05
compared to uaSMCs; n=3]. (E) MPCs were immunostained for antibodies against membrane-bound proteins CD90, NG2, and PDGFR-b, and
cytoplasmic protein a-SMA. [Blue: DAPI for nuclear staining; Green: Alexa Fluorochrome 488; scale bar represents 100 mm].
doi:10.1371/journal.pone.0038752.g001
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measured these transcription factors at day 14. Surprisingly, we
found that cells exposed to differentiation media alone (i.e. normal
glucose levels), significantly downregulated early chondrogenesis
genes Sox9 and Nkx3.2 (Figure 7A–C). At this time point, cells
exposed to high levels of glucose exhibited significantly higher
levels of both Sox9 and Nkx3.2 (Figure 7B and 7C). Recently, it
has been shown that unlike the adipogenesis-specific and
osteogenesis-specific transcription factors (determined above),
Sox9 plays an essential stage-specific role in chondrogenesis
[23]. To test whether high glucose may be delaying these
differentiation steps (Figure 7A), we measured Runx2 (late marker
of chondrogenesis) in our assay. Our results show that bmMPCs
induce Runx2 at day 14, which coincides with repressed Sox9 and
Nkx3.2 (Figure 7D). In contrast, cells exposed to high glucose
showed significantly lower Runx2 levels.
Discussion
The present study demonstrates the differential response of
vascular progenitor cell populations and mature cells to high levels
of glucose. The salient findings of our study are that: 1) high levels
of glucose do not alter derivation of bona fide EPCs and MPCs, 2)
there is no significant cellular dysfunction in the abEPCs, unlike
mature ECs, and 3) MPCs undergo significant cellular changes in
high glucose conditions displaying altered differentiation potential.
Figure 2. Cells were cultured in 5 mmol/L (control) or 25 mmol/L (high glucose; HG) glucose throughout the completion of each
cellular activity assay. In all graphs, values indicate mean 6 SEM. (A) Growth of abEPCs was assessed as cell viability over a 12 day period in high
serum media (EBM2/20% FBS). A spike in activity occurred in the hyperglycemic group at day 6 (*p,0.05 compared to cells in control media).
However, abEPCs showed no significant differences between control and HG-treated groups over long-term culture. (B) Caspase-3 activity level was
measured in abEPCs and HDMECs exposed to control or HG media (in EBM-2/1% FBS) for 24 hours [*p,0.05 compared to respective control media;
{p,0.05 compared to HDMECs in HG media; n=3]. (C) A 24-hour migration assay was performed on abEPCs, assessed as their ability to migrate
through an 8-mm pore with bFGF as the chemoattractant. HG had no effect on the migratory abilities of abEPCs, cbEPCs, and HDMECs. (D) Growth of
bmMPCs was assessed as cell viability over a 12 day period in high serum media (DMEM/20% FBS). HG-bmMPCs showed significantly less growth at
day 1 as compared to control (*p,0.05). However, growth over long-term culture appeared to be unaffected by HG. (E) Migration of bmMPCs was
assessed in the presence of 10% FBS as the chemoattractant. Exposure of bmMPCs to HG significantly reduced the migratory ability towards FBS
(*p,0.05).
doi:10.1371/journal.pone.0038752.g002
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biochemical alterations in vascular ECs [27], resulting in impaired
function [24,27,28]. These changes are evident when ECs are
cultured in serum-free media containing high levels of glucose.
Our studies do show increased caspase-3 activity (molecular
correlate of apoptosis) in HDMECs exposed to high levels of
glucose. Under identical conditions, caspase-3 activity level was
significantly different in abEPCs as compared to HDMECs.
Furthermore, this toxic effect was found to be acute (evident within
24 hours). Long-term culture of abEPCs in high levels of glucose
did not alter cell activities. It should be noted that long-term
assessment of cellular activity necessitated the use of serum in the
media, which may mask the toxic effect of glucose. However, these
conditions are consistent with early-stage changes in diabetes. Two
recent studies have demonstrated a lower circulating number of
EPCs (CD34+/VEGFR2+/CD31+) in both type 1 and type 2
diabetic patients [29,30]. Further, the number of CD34+/
VEGFR2+ cells has been shown to correlate with glycemic
control, and negatively associate with arterial stiffness in diabetic
patients [31]. This may be because of the acute effect of
hyperglycemia as the EPCs are mobilized from the bone marrow.
Although compelling, these recent findings also potentially take
into account a reduction in hematopoietic stem/progenitor cells
that share some of these same surface markers. An interesting
future direction would be to pre-treat abEPCs in culture and then
administer in diabetic animals to assess whether the toxic effects of
hyperglycemia are evident.
Unexpectedly, we found that the progenitor population most
affected by high glucose is the mesenchymal cell type. When we
cultured bone marrow-derived MPCs in high glucose media, we
noted a significant reduction in cell numbers at day 1. However,
this effect was normalized upon continued exposure. This is a
novel finding, as not much research to date has linked diabetes
with changes in cells of the mesenchymal lineage. A recent study,
however, has indicated that advanced glycation end products may
be responsible for an increase in reactive oxygen species and
Figure 3. Gene expression profiles of abEPCs. Cells were cultured
in 5 mmol/L (control) or 25 mmol/L (high glucose; HG) glucose for up
to 14 days. RNA was isolated at day 1, day 3 (data not shown), and
day 14 (data not shown) in order to assess changes in gene expression
through qRT-PCR. (A) Endothelial cell activation was examined through
expression of vasoconstrictor endothelin-1 (ET-1) and adhesion
molecules E-Selectin and ICAM1. Contrary to what we expected, HG-
treated abEPCs, cbEPCs, and HDMECs showed no significant changes in
ET-1, E-selectin, and ICAM1 as compared to controls. (B) A panel of
known oxidative stress markers were examined in abEPCs, cbEPCs, and
HDMECs. (C) The extracellular matrix (ECM) protein profile of abEPCs,
cbEPCs, and HDMECs was examined by comparing levels of fibronectin,
collagens 1,3, and 4. No significant alteration in ECM proteins was noted
in abEPCs, cbEPCs, and HDMECs.
doi:10.1371/journal.pone.0038752.g003
Figure 4. Gene expression profiles of bmMPCs. Cells were
cultured in 5 mmol/L (control) or 25 mmol/L (high glucose; HG) glucose
for up to 14 days. RNA was isolated at day 1, day 3 (data not shown),
and day 14 (data not shown) in order to assess changes in gene
expression through qRT-PCR. (A) Oxidative stress marker expression in
bmMPCs and uaSMCs showed no significant changes upon exposure to
high levels of glucose. (B) HG induced an increase in the production of
matrix proteins in mature uaSMCs, but caused downregulation of these
same markers in the bmMPCs [*p,0.05 compared to control media;
n=3].
doi:10.1371/journal.pone.0038752.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38752Figure 5. Differentiation of bmMPCs into adipocytes. bmMPCs were cultured in 5 mmol/L (control glucose) or 25 mmol/L (high glucose; HG)
glucose for 7 days prior to differentiation and assessed for induction of PPARc2 and C/EBPa (A). HG-treated bmMPCs increased adipogenesis at day 7,
as demonstrated by upregulated PPARc2 levels (B) and C/EBPa (C). Analysis of cells at day 14 showed increased PPARc2 upon differentiation but no
differences between control- and HG-treated cells. C/EBPa levels (E), on the other hand, were significantly higher in HG-treated cells at day 14 as
compared to control glucose treated cells [*p,0.05 compared to control media; {p,0.05 compared to cells treated with control glucose +
differentiation media].
doi:10.1371/journal.pone.0038752.g005
Figure 6. Differentiation of bmMPCs into osteocytes. bmMPCs were cultured in 5 mmol/L (control glucose) or 25 mmol/L (high glucose; HG)
glucose for 7 days prior to differentiation and assessed for induction of Runx2 and SP7 (A). (B) 14-day differentiation of bmMPCs into osteocytes
showed significantly depressed expression of Runx2 and SP7 in HG treated cells [*p,0.05 compared to control media; {p,0.05 compared to cells
treated with control glucose + differentiation media].
doi:10.1371/journal.pone.0038752.g006
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marrow-derived MPCs [32].
MPCs exhibit remarkable plasticity, with the ability to differen-
tiate both in vitro and in vivo into a number of mesenchymal
phenotypes including those that form bone, cartilage, muscle, fat,
and other connective tissues [33235]. In addition to affecting
bmMPC growth and migration, high glucose caused a very
prominent change in their differentiation potential. Hyperglycemic
bmMPCs exhibited enhanced adipogenesis (assessed by PPARc2
andC/EBPainductionlevels)whencomparedtocontrolcells,while
their ability to differentiate into alternate lineages (chondrocytes,
osteocytes) was impaired. Much research to date has implicated the
Wnt/beta-catenin signaling pathway as a major regulator of this
process [36,37]. Down-regulation of this pathway increases
adipogenesis, whereas the use of specific Wnt proteins in vitro has
successfully inhibited differentiation to adipocytes [38]. Whether
hyperglycemia directly alters the Wnt pathway, leading to skewed
differentiation into adipocytes, remains to be determined.
These studies demonstrate the differing response of mature cells
and progenitor cells to high levels of glucose. We have confirmed
that hyperglycemia has a toxic effect on mature ECs, inducing
significant increases in apoptosis- a notion that has been well-
established in diabetes research. Conversely, our studies indicate
that both EPCs and MPCs may be useful therapeutic agents in
diabetes. Although the cellular activity (growth and migration) of
bmMPCs was disrupted initially, high glucose had little effect on
both progenitor cell populations over the long-term. Therefore,
increasing the number of vascular stem/progenitor cells and
negating the initial toxic effect of hyperglycemia in diabetic
patients may prove to be an effective means of restoring vascular
homeostasis in diabetes.
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